Bjerkenstedt L, Härnryd C, Sedval G
Psychopharmacology (Berl). 1979 Aug 8;64(2):135-9. doi: 10.1007/BF00496053.
Concentrations of the major monoamine metabolites homovanillic acid (HVA) 4-hydroxy-3-methoxyphenylethylene glycol (MOPEG), and 5-hydroxyindoleacetic acid (5-HIAA) were determined in lumbar CSF of psychotic women with a schizophrenic symptomatology before and 4 weeks after treatment with sulpiride (Dogmatil 200 mg x 4). The metabolites were determined by a mass fragmentographic method. Prolactin concentrations in CSF and plasma were determined by radioimmunoassay. The clinical effects were evaluated by ratings according to the comprehensive psychopathology rating scale (CPRS) and a scale for side effects. Levels of HVA and prolactin in CSF and plasma were significantly elevated during treatment. No effects on concentrations of MOPEG or 5-HIAA were observed. The biochemical data indicate that clinical doses of sulpiride blocked dopamine receptors in the nigrostriatal pathway as well as in the tuberoinfundibular system. Treatment with sulpiride was associated with marked reductions in psychotic morbidity.
采用质谱碎片分析法测定了有精神分裂症症状的精神病女性患者在使用舒必利（舒多普利200毫克×4）治疗前及治疗4周后腰椎脑脊液中主要单胺代谢物高香草酸（HVA）、4-羟基-3-甲氧基苯乙二醇（MOPEG）和5-羟基吲哚乙酸（5-HIAA）的浓度。通过放射免疫分析法测定脑脊液和血浆中的催乳素浓度。根据综合精神病理学评定量表（CPRS）和副作用量表对临床疗效进行评定。治疗期间脑脊液和血浆中的HVA和催乳素水平显著升高。未观察到对MOPEG或5-HIAA浓度有影响。生化数据表明，临床剂量的舒必利阻断了黑质纹状体通路以及结节漏斗系统中的多巴胺受体。舒必利治疗与精神病发病率显著降低有关。
